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Abstract
Epigenetics is a key mechanism regulating the expression of genes. There are three main and interrelated
mechanisms: DNA methylation, post-translational modification of histone proteins and non-coding RNA.
Gene activation is generally associated with lower levels of DNA methylation in promoters and with distinct
histone marks such as acetylation of amino acids in histones. Unlike the genetic code, the epigenome is
altered by endogenous (e.g. hormonal) and environmental (e.g. diet, exercise) factors and changes with
age. Recent evidence implicates epigenetic mechanisms in the pathogenesis of common rheumatic dis-
ease, including RA, OA, SLE and scleroderma. Epigenetic drift has been implicated in age-related changes
in the immune system that result in the development of a pro-inflammatory status termed inflammageing,
potentially increasing the risk of age-related conditions such as polymyalgia rheumatica. Therapeutic
targeting of the epigenome has shown promise in animal models of rheumatic diseases. Rapid advances
in computational biology and DNA sequencing technology will lead to a more comprehensive understand-
ing of the roles of epigenetics in the pathogenesis of common rheumatic diseases.
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ment, ageing, therapeutic targeting.
Introduction
Although most cells have the same DNA sequence, the
activity of individual genes differs significantly between
different cell types and tissues, e.g. the insulin gene is
highly compacted in structure and inactive in all tissues
except pancreatic b cells, in which it is in an open con-
formation that facilitates transcription. Epigenetics has
been defined as heritable changes in gene expression
that are not encoded by the DNA sequence itself [1].
Unlike the latter, it is dynamic and changes under the
influence of endogenous and environmental factors. The
role of epigenetics in health and disease is emerging; it
has been established that carcinogenesis is frequently
associated with epigenetic alterations that are potential
therapeutic targeting [2, 3]. Our objectives are to give
overviews of the epigenetic mechanisms regulating gene
expression, their involvement in the pathogenesis of
common musculoskeletal conditions and their potential
as therapeutic targets.
Epigenetic mechanisms
Three major interrelated mechanisms regulate gene
expression: DNA methylation, post-translational modifica-
tion of histone proteins and non-coding RNA (ncRNA).
DNA methylation
In plants, yeasts and animals, methylation of DNA mainly
occurs at the cytosine (C) residues of DNA in CpG di-
nucleotide motifs and is regulated by DNA methyltrans-
ferase (DNMT) enzymes. Overall, CpG motifs are
predominantly methylated, except in CpG-rich regions of
200300 bp in the 50 region of many genes, termed CpG
islands, which are mainly unmethylated. In general the
regions around the transcriptional start site of active
genes have low levels of methylation [4]; conversely,
gene bodies are methylated [5]. In macrophages, for
example, methylation of CpG motifs in the TNF promoter
within 200 bp of the transcriptional start site is low, at
20%, while upstream CpG motifs have levels >80%
[6]; similar findings have been described in IL-6 [7].
Greater variability exists in DNA methylation levels be-
tween different tissues from an individual than in identical
1Center of Experimental Rheumatology, University Hospital Zurich,
Gloriastrasse 25, 8091 Zurich, Switzerland and 2Department of
Infection and Immunity, University of Sheffield, Sheffield, UK.
Correspondence to: Anthony G. Wilson, Department of Infection and
Immunity, University of Sheffield, Royal Hallamshire Hospital, Sheffield
S10 2JF, UK. E-mail: a.g.wilson@sheffield.a.uk
Submitted 28 February 2013; revised version accepted 22 July 2013.
! The Author 2013. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com
RHEUMATOLOGY
Rheumatology 2014;53:406414
doi:10.1093/rheumatology/ket292
Advance Access publication 11 September 2013
R
E
V
IE
W
tissues from different individuals [8]. The existence of DNA
demethylating enzymes is generally accepted, but the
molecular mechanisms are poorly understood and are
believed to involve the enzyme ten-eleven translocation
1 (TET1) [9]. Demethylation is an important mechanism
governing gene activation; the IL-2 promoter demethy-
lates within 20 min of activation of T cells [10], facilitating
binding of the transcription factor Oct-1 [11].
Epigenetics also regulates alternative splicing [12] and
promoter usage [5], processes that add significantly to the
complexity of the expressed genome. Furthermore, in dip-
loid cells 5% of genes are monoallelically expressed
[13]; in lymphoblastoid cells this affects a disproportion-
ately high number of cell surface proteins and cytokines
(IL-2, 4, 5 and 13) [14, 15]. It seems likely that this
phenomenon is mediated by allele-specific methylation
[16, 17]. Genetic variants influence the variability of DNA
methylation levels between individuals, however, the her-
itability of this trait has not been determined [18].
Histone code
More than 100 post-translational modifications of the
N-terminal tails of histone proteins have been described,
including acetylation, methylation, phosphorylation and
sumoylation [19]. These result in changes in the structure
of nucleosomes, altering access of the transcriptional ma-
chinery and transcriptional activity (Fig. 1). The histone
code is linked with DNA methylation by distinct, but
coupled, pathways [20]. Histone acetylation is considered
a permissive transcriptional mark, while trimethylation is
associated with repression [21, 22]. Histone acetylation
and phosphorylation are rapidly modifiable, while methy-
lation is more stable; the terminal transferase gene (Dntt)
undergoes silencing during thymocyte maturation
characterized by initial deacetylation of H3-Lys9 and sub-
sequent methylation at H3-Lys9, the latter being irrevers-
ible [23]. The deacetylation at H3-Lys9 begins in the
promoter region (500 kb on either side of the transcrip-
tional start site) and then spreads across the Dntt locus
(22 kb) at a rate of 2 kb/h. Deacetylation is reversible, but
the subsequent methylation at H3-Lys4 is not and results
in permanent silencing of Dntt.
Non-coding RNAs
The coding exons of genes comprise 1.5% of the human
genome. It has recently become clear from the
Encyclopedia of DNA Elements (ENCODE) project that a
large proportion of the genome codes for non-protein
coding RNA species that have important roles in regulat-
ing the transcriptome [24]. ncRNAs are primarily classified
according to size: short (2060 bp), mid-size (60200 bp)
and long (>200 bp). There is a large body of evidence
implicating disrupted expression of ncRNAs in neoplastic
and inflammatory diseases [25]. MicroRNAs (miRNAs) are
short ncRNA molecules that regulate gene expression
mainly by targeting the cognate RNA molecule for deg-
radation or translational inhibition. In addition, several
miRNAs alter gene expression by binding to complemen-
tary sequences in gene promoters with resultant
alterations in the histone signature [26]. There is significant
cross-regulation of the three epigenetic mechanisms: ex-
pression of many miRNAs are modulated by DNA methy-
lation and histone modifications (reviewed in [27]), and
miRNAs have been shown to target key proteins regulat-
ing the epigenome; expression of DNMT3A and DNMT3B
are modulated by miR-29 [28], and HDAC1 and HDAC4
are targeted by miR-449a [29] and miR-1 [30],
respectively.
Epigenetic influences in RA
Synovial fibroblasts
The RA fibroblast-like synoviocytes (RASFs) are central
mediators of tissue destruction via the production of a
range of disease-related molecules, including chemo-
kines, adhesion molecules and proteases [31]. In addition,
RASFs have a semi-transformed phenotype in vitro, with
loss of contact inhibition, high proliferative activity and
resistance to apoptosis. Engraftment of normal human
cartilage and RASFs into the severe combined immuno-
deficiency mouse revealed this aggressive phenotype to
be maintained for up to 60 days and be independent of
adaptive immune cells [32, 33]. The mechanism(s) respon-
sible for this stable, aggressive phenotype is unknown,
however, there is increasing evidence implicating the epi-
genome. A methylation array study reported lower levels
in RASFs compared with OA synovial fibroblasts (OASFs),
particularly in genes regulating cell adhesion, transen-
dothelial migration and extracellular matrix interactions
[34]. Furthermore, treating OASFs with the DNA demethy-
lating agent 5-azadeoxycytidine (AZA) resulted in conver-
sion to an RASF-like phenotype [35]. Decreased
expression of miR-34a*, as a result of increased promoter
methylation, results in up-regulation of the X-linked inhibi-
tor of apoptosis protein, potentially contributing to the
resistance of RASFs to apoptosis [36].
The acetylation of histone proteins is regulated by the
relative activities of two enzyme families: histone acet-
yltransferases and histone deacetylases (HDACs). The
HDAC superfamily is important in the regulation of a wide
range of developmental and physiological processes [37].
As HDACs lack DNA-binding activity, they are recruited to
target genes via interactions with transcription factors. A
shift towards histone hyperacetylation has been reported
in RASFs compared with OASFs [38, 39], with overexpres-
sion of HDAC1 in the former [39]. Targeted knockdown of
HDAC1 in RASFs, using small interfering RNA, resulted in
decreased proliferation and increased apoptosis [40].
Peripheral blood
Global DNA methylation has been reported to be lower in
T cells [41] and leucocytes [42] of RA patients compared
with controls, although both involved small numbers. A
single CpG motif in the IL-6 promoter, 1 kb upstream
of the transcriptional start site, was significantly less
methylated in peripheral blood mononuclear cells from
RA cases compared with controls, and correlated with
higher lipopolysaccharide-induced IL-6 mRNA levels by
www.rheumatology.oxfordjournals.org 407
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monocyte-derived macrophages [7]. Higher expression of
CD40L and lower promoter methylation is found in RA
CD4 T cells [43].
Epigenetic influences in OA
The underlying pathogenic mechanisms of OA are poorly
understood but involve genetic and environmental factors.
Studies of the role of the epigenome have concentrated
on chondrocytes. Genomic DNA methylation levels were
found to be similar in chondrocytes from 10 OA and 10
normal joints [44], however, the levels of methylation of
the leptin promoter were lower in chondrocytes isolated
from severely involved cartilage compared with minimally
involved or normal cartilage and were associated with
greater expression of this catabolic cytokine and its
downstream target MMP (MMP-3) [45]; similar findings
have been reported in MMP-9, MMP-13 and ADAMTS (a
disintegrin and metalloproteinase with a thrombospondin
type 1 motif) [46]. Of particular note is the finding of lower
ADAMTS-4 promoter methylation and higher expression
in lesional compared with non-lesional chondrocytes [47].
Nitric oxide (NO), a key signalling molecule, is produced at
high levels by activated chondrocytes [48] and mediates
IL-1b-induced suppression of cartilage proteoglycan syn-
thesis [49]. Lesional chondrocytes express high levels of
inducible NO synthesis (iNOS) and have reduced methy-
lation of a nuclear factor kB (NF-kB) enhancer element
5.8 kb upstream of the iNOS transcriptional start site
[50]. These studies reveal the importance of comparing
the epigenetic profiles of chondrocytes from lesional and
non-lesional cartilage within the same OA joint.
Epigenetic influences in SLE
Alterations in the epigenome have been implicated in both
idiopathic and drug-induced lupus. Lower levels of gen-
omic DNA methylation have been reported in peripheral T
cells from lupus patients compared with healthy controls
[41], and adoptive transfer of T cells that have been treated
with AZA induces a lupus-like condition in syngeneic mice
[51]. Incubation of human T cells with this agent results in
alterations in gene expression similar to those found in idio-
pathic lupus, including the up-regulation of CD11a [52]. An
additional epigenetic abnormality in lupus T cells is the
reduced expression of DNMT1 secondary to decreased
FIG. 1 Epigenetic modifications control the transcriptional status of genes.
In the upper panel DNA methylation (red) and chemical changes in histone tails, such as lysine acetylation, resulted in a
closed chromatin structure and resultant repression of transcription. Conversely, DNA demethylation (light yellow) and
histone modifications, such as lysine deacetylation, resulted in an open chromatin structure and transcriptional
activation.
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activity of Ras-mitogen-activated protein kinase [53]. It is
notable that the drugs associated with the development of
iatrogenic lupus, procainamide and hydralazine, have been
shown to be functional inhibitors of DNMT, potentially
resulting in DNA hypomethylation [54, 55].
SSc
A central feature of SSc is tissue fibrosis mediated by inter-
stitial fibroblasts. These cells have an altered phenotype,
both in vivo and in vitro, characterized by excessive depos-
ition of extracellular matrix proteins including collagens [56,
57]. The maintenance of this phenotype in vitro has been
correlated with higher levels of DNMT1 [57, 58] and treat-
ment with DNA demethylating agents in vitro results in
reduced expression of collagen by dermal fibroblasts
from SSc patients, but has no effect on fibroblasts from
healthy controls [57]. A major suppressor of collagen tran-
scription is FLi1, which is down-regulated in SSc dermal
fibroblasts [59]. This alteration is associated with higher
methylation of a CpG island in the FLi1 promoter [57].
These data suggest that higher DNA methylation is present
in SSc dermal fibroblasts and may be an important mech-
anism governing the overproduction of collagen.
Expression of miR-29, which targets collagen gene
transcripts, is lower in SSc dermal fibroblasts compared
with fibroblasts from controls, and overexpression in the for-
mer resulted in decreased collagen gene expression [60].
The epigenome as a therapeutic target
The pathways regulating the epigenome are attractive
therapeutic targets in rheumatic diseases. A key issue is
developing agents that target a limited number of disease-
related genes and to do this effectively will require a much
greater understanding of regulatory pathways. Progress is
being made, however, as shown by the development of a
small molecule targeting the catalytic domain of an
enzyme responsible for the demethylation of a single
amino acid in the histone 4 protein. This results in pro-
found anti-inflammatory activities in macrophages [61].
Therapeutic targeting of HDACs
RA
In animal models of RA, HDAC inhibitors (HDACis) have
been shown to be effective therapeutic agents.
Autoantibody-mediated arthritis is attenuated by a single
intravenous infusion of FK228, an inhibitor of HDAC1 and
2, inhibiting of synovial swelling and bone and cartilage
loss, reduced TNF and IL-1b production and cell cycle
arrest via the up-regulation of p21 [62]. This agent also
inhibits in vitro proliferation of RASFs [62]. Knockdown
of HDAC1 in RASFs by small interfering RNA resulted in
decreased proliferation and increased apoptosis [40]. The
superior efficacy of MS-275 over other HDACis in colla-
gen-induced arthritis has been proposed to be due to its
specificity for class I HDACs, particularly HDAC1 [63].
These data implicate HDAC1 as a key regulator of the
autoaggressive phenotype of RASFs. A small study has
recently reported that Givinostat, a class I and II HDACi,
was both efficacious and safe in a 12-week trial involving
17 patients with systemic-onset JIA [64].
OA
The majority of studies to date have examined the effects
of HDACis on chondrocytes and cartilage explants.
Inhibition of class I and II HDACs using sodium butyrate
or trichostatin A (TSA) resulted in the blocking of pro-
inflammatory cytokineinduced cartilage breakdown and
suppression of matrix degrading protease production,
including MMP-1 and MMP-13 and ADAMTS-4, -5 and
-9 [65]. These agents also prevented the IL-1b-induced
release of IL-17, TNF, prostaglandin E2 and NO by chon-
drocytes [66]. The only published in vivo study involved
systemic treatment of a rabbit model of OA with TSA,
which resulted in reduced cartilage loss and metallopro-
teinase expression [67].
SLE
Administration of TSA to MRL/lpr mice resulted in reduced
expression of IL-6, -10 and -12 and lessening of renal
damage and splenic weight [68], and broadly similar results
were obtained after administration of this agent to NZB/W
F1 mice [69]. Aberrant gene expression is a feature of
helper T cells in lupus, including up-regulation of CD40L
(CD154) and IL-10, and down-regulation of IFN-g, these
alterations can be reversed by incubation with TSA [70].
Scleroderma
Transforming growth factor b (TGF-b) controls the produc-
tion of type 1 collagen synthesis by dermal fibroblasts. This
activity can be suppressed by TSA via the down-regulation
of Sp1 activity [71] and the inhibition of DNA binding of the
profibrotic Smad transcription factors [72]. In addition, TSA
inhibits HDAC-7 expression by SSc fibroblasts. Silencing of
HDAC-7 expression results in decreased constitutive and
cytokine-induced production of collagen [73].
Epigenetics and inflammageing
Ageing is associated with an increased risk of developing
a large number of inflammatory rheumatic diseases [74].
Many features of both the adaptive and innate immune
systems change with increasing age, leading to a state
of increased activity termed inflammageing [75]. In the
adaptive system, changes include reduced generation of
high-affinity antibodies after immunization [76] and reduc-
tion in the naive T cell population [77]. Innate immune
system changes include both higher systemic levels of
proinflammatory cytokines and increased lipopolysac-
charide (LPS)-induced production of TNF and IL-6 by
macrophages [78, 79]. Age-related functional changes
occur in granulocytes, including decreased chemotaxis,
phagocytosis and superoxide generation in response to
danger signals [80]. Neutrophils of elderly individuals
exhibit decreased expression of CD16 (FcgRIIIa) [81] and
have alteration of mitogen-activated protein kinase (MAPK)
activation, contributing to the inability of GM-CSF to
www.rheumatology.oxfordjournals.org 409
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decrease caspase-3 activation, leading to reduced clear-
ance of apoptotic neutrophils [82]. These studies suggest a
complex pattern of age-related changes in gene expres-
sion in different immune cells that may result in an
increased risk of inflammatory disorders (Fig. 2).
There is evidence suggesting a role of epigenetic drift in
inflammageing. Age-related divergence of the epigenetic
signature in peripheral blood has been reported in mono-
zygotic twins; the patterns of global and gene-specific
DNA methylation are similar in early life, however, older
twins (age >50 years) have marked differences, particu-
larly if they were separated early in life [83]. A longitudinal
study of the methylation status of 1505 CpG motifs in 807
genes reported changes in immune genes, including IL-10
and IL-16 [84]. Levels of methylation of CpG motifs in the
TNF promoter gradually decease with age, by 1.4% per
decade in macrophages, and may be a mechanism of the
age-related increased systemic levels of this key proin-
flammatory cytokine [6]. Inflammation per se can lead to
alteration in the epigenetic signature via the effects of re-
active radicals oxidizing 5-methylcytosines to 5-hydroxy-
methlycytosine, with subsequent loss of methylation.
Conversely the production of reactive halogen molecules,
such as HOCl and HOBr, by activated leucocytes can
result in the incorporation of halogen cytosine into DNA
with subsequent increased methylation [85].
Epigenome and environmental exposures
The complex relationship between the epigenome and
lifestyle factors is emerging. Dietary intake of nutrients,
such as folate, is known to affect DNA methylation [86].
Regular exercise has been shown to increase methylation
of the ASC locus, encoding a component of the NALP3
inflammasome, potentially resulting in reduced levels of
proinflammatory cytokines [87]. Cigarette smoking has
been linked with alterations in both global DNA methyla-
tion and in genes controlling cellular proliferation [88]. An
array scan of 14 000 gene promoters reported lower
methylation of F2RL3 [89], intriguingly F2RL2 has been
linked with platelet activation and intimal hyperplasia,
two of the mechanisms central in the pathogenesis of
smoking-related vasculopathy.
Conclusions
There is increasing evidence implicating the epigenome
with the development of inflammatory and age-related
rheumatic diseases (Table 1). The complexity of the epigen-
etic signature and its dynamic nature, the differences be-
tween cell types and tissues and the potential effects of
inflammation on the epigenome complicate studies in
rheumatic diseases. Initial attempts have concentrated on
candidate genes in specific cell types that are known to be
implicated in diseases such as synovial or dermal fibro-
blasts in RA and SSc, respectively, lymphocytes in SLE
and chondrocytes in OA. It is important to note, however,
that many of studies have been of low power and have not
included a validation study. An additional issue is that many
have examined mixed cell populations and it is important to
be aware that even a purified cell population such as CD4 T
cells includes a heterogeneous mixture of T cell types.
FIG. 2 Ageing is associated with epigenetic drift with resultant increased risk of inflammatory conditions.
Environmental exposures during life affect the epigenetic signature of genes resulting in a gradual loss of control of gene
expression in different tissues. These changes in immune and inflammatory cells result in the development of inflam-
mageing with increased risk of age-related inflammatory diseases.
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Additional issues to be considered are that epigenetic
differences may arise secondary to disease or therapies.
A recent RA study highlighted novel computational
approaches to deal with these confounders [90]. The epi-
genome is an attractive therapeutic target and in vitro and
in vivo studies with HDACis have shown promising results
in rheumatic diseases. However, greater therapeutic speci-
ficity is required to minimize side effects, and this will re-
quire a greater understanding of the molecular mechanisms
controlling the epigenome. Recent studies targeting spe-
cific epigenetic marks with small molecules may prove
effective [62]. Recent rapid advances in high-throughput
technologies and computational biology should ensure
that epigenome-wide association studies in cell types impli-
cated in rheumatic diseases will be performed in the near
future. This will lead to significant improvements in our
understanding of their pathogenesis of these conditions
and lead to improved therapeutic strategies [91].
Rheumatology key messages
. Epigenetics factors have been implicated in the
pathogenesis of common rheumatic diseases
including RA, OA, SLE, and SSc.
. Environmental exposures and ageing are asso-
ciated with changes in the epigenetic signature
and expressed genome.
. Therapeutic targeting of the epigenome has shown
efficacy in animal models of RA and preliminary
studies in patients.
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